Analysts believe hopefully the tide may turn this year and some of the leading companies like Dr Reddy's that are still facing regulatory challenges may get some relief.

Reports say that both JSW and Tata look to submit bids for Usha Martin's 1 MT steel unit.

The development is a hugely positive development both for Sun Pharma and for Indian pharma. From a sentiment perspective, it is significant given that the company has been finally able to get its facility cleared after three years.

To begin with, according to industry insiders, rising crude is putting pressure on rupee already stressed by widening fiscal deficit.

Employees prefer a work environment that helps them grow professionally, honing and adding totheir skills, reveals a Business Today-PeopleStrong survey.

Pegged at over Rs 18,862 crore by a Nicholas Hall 2017 report, the Indian OTC market is expected to grow at a compounded annual growth rate (CAGR) of 9 percent to cross Rs 44,115 crore.

By following the strategy of doing a few things well, V.C. Nannapaneni has helped Natco Pharma carve out a space for itself.

Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.